New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 15, 2013
12:30 EDTPRGOPerrigo announces launch of betamethasone valerate foam 0.12%
Perrigo announced that it has begun commercial shipments of betamethasone valerate foam 0.12%, the generic equivalent of Luxiq Foam, consistent with the date certain launch settlement previously announced. Cobrek Pharmaceuticals, , which was recently acquired by Perrigo, was first to file, making the product eligible for 180 days of marketing exclusivity. Perrigo is entitled to receive 100% of the profits from net sales of the product due to the Cobrek acquisition. Betamethasone valerate foam 0.12% is indicated for the relief of corticosteroid-responsive skin conditions of the scalp (scalp psoriasis). Brand annual sales were approximately $40M as measured by Symphony Health.
News For PRGO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
09:39 EDTPRGOPerrigo in exclusive talks to buy Omega Pharma, Bloomberg says
Subscribe for More Information
09:18 EDTPRGOPerrigo in exclusive talks to buy Omega Pharma, Bloomberg says
Subscribe for More Information
October 21, 2014
06:44 EDTPRGOActavis among bidders for Omega Pharma, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use